GetTopicDetailResponse(id=7e55322e20f, topicName=利匹韋林, introduction=利匹韋林, content=null, image=null, comments=5, allHits=1135, url=https://h5.medsci.cn/topic?id=32272, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=55138, tagList=[TagDto(tagId=55138, tagName=利匹韋林)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1952419, encodeId=19fa19524191c, content=<a href='/topic/show?id=7e55322e20f' target=_blank style='color:#2F92EE;'>#利匹韋林#</a>, objectTitle=Lancet：每8周1次的長(zhǎng)效卡博特韋-利匹韋林治療方案用于HIV感染者的治療, objectType=article, longId=204396, objectId=a3fe20439667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3fe20439667, replyNumber=0, likeNumber=97, createdTime=2021-05-30, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3fe20439667, moduleTitle=Lancet：每8周1次的長(zhǎng)效卡博特韋-利匹韋林治療方案用于HIV感染者的治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a3fe20439667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952417, encodeId=ed7f195241e03, content=<a href='/topic/show?id=7e55322e20f' target=_blank style='color:#2F92EE;'>#利匹韋林#</a>, objectTitle=BMC Infectious Diseases ：利匹韋林和整合酶抑制劑治療HIV患者的病毒學(xué)抑制耐久性, objectType=article, longId=162525, objectId=12c116252582, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12c116252582, replyNumber=0, likeNumber=93, createdTime=2019-07-17, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12c116252582, moduleTitle=BMC Infectious Diseases ：利匹韋林和整合酶抑制劑治療HIV患者的病毒學(xué)抑制耐久性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=12c116252582)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952418, encodeId=1e3419524186b, content=<a href='/topic/show?id=7e55322e20f' target=_blank style='color:#2F92EE;'>#利匹韋林#</a>, objectTitle=BMC Infectious Diseases：從蛋白酶抑制劑轉(zhuǎn)換為利匹韋林或整合酶抑制劑后患者血脂得到改善, objectType=article, longId=162546, objectId=1c931625464e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c931625464e, replyNumber=0, likeNumber=93, createdTime=2020-02-05, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c931625464e, moduleTitle=BMC Infectious Diseases：從蛋白酶抑制劑轉(zhuǎn)換為利匹韋林或整合酶抑制劑后患者血脂得到改善, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1c931625464e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952416, encodeId=9b53195241690, content=<a href='/topic/show?id=7e55322e20f' target=_blank style='color:#2F92EE;'>#利匹韋林#</a>, objectTitle=Lancet：度魯特韋聯(lián)合利匹韋林治療HIV-1型III期臨床研究, objectType=article, longId=125930, objectId=85ca1259307a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ca1259307a, replyNumber=0, likeNumber=81, createdTime=2018-09-25, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ca1259307a, moduleTitle=Lancet：度魯特韋聯(lián)合利匹韋林治療HIV-1型III期臨床研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=85ca1259307a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1952415, encodeId=2f5b1952415c0, content=<a href='/topic/show?id=7e55322e20f' target=_blank style='color:#2F92EE;'>#利匹韋林#</a>, objectTitle=Lancet：長(zhǎng)效抗病毒藥物Cabotegravir和利匹韋林聯(lián)合用于維持HIV-1病毒抑制期的效果, objectType=article, longId=106586, objectId=4e2b1065868d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2b1065868d, replyNumber=0, likeNumber=99, createdTime=2018-03-04, rootId=0, userName=yangjxjc, userId=6e43278, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2b1065868d, moduleTitle=Lancet：長(zhǎng)效抗病毒藥物Cabotegravir和利匹韋林聯(lián)合用于維持HIV-1病毒抑制期的效果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4e2b1065868d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
